Bacterial Vaginosis (BV) is an infection caused by an imbalance in the amount of naturally occurring bacteria in the vagina. Bacterial Vaginosis is relatively common and often treated with antibiotics.
The most common drug used to treat Bacterial Vaginosis is metronidazole. It is taken orally or applied as a gel, cream, or lotion to the vagina directly. Metronidazole works by killing the bacteria associated with Bacterial Vaginosis.
Bacterial Vaginosis is a common vaginal infection, especially among women ages 15 to 44. According to the World Health Organization, up to 50 percent of women in this age group are affected by Bacterial Vaginosis, making it one of the most common causes of vaginal infections in this age group.
Bacterial Vaginosis is also more common among those with multiple sexual partners or those who use vaginal douching. Bacterial Vaginosis is generally more common in developing countries due to lack of access to medical care.
Despite the frequency of the infection, there is a lack of research on the prevalence of Bacterial Vaginosis globally. This means that the available information is limited, further complicating the accurate diagnosis and treatment of the infection.
The global Bacterial Vaginosis Drug market was valued at US$ 946.3 million in 2022 and is anticipated to reach US$ 1130 million by 2029, witnessing a CAGR of 3.0% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
A detailed market research report on Global Bacterial Vaginosis Drug Market available at: https://www.themarketreports.com/report/global-bacterial-vaginosis-drug-market-research-report
This report aims to provide a comprehensive presentation of the global market for Bacterial Vaginosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bacterial Vaginosis Drug.
Global Bacterial Vaginosis Drug key players include Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. Global top five manufacturers hold a share about 20%. North America and Europe is the largest market, both with a share about 30%, followed by China, with a share about 10 percent. In terms of product, OTC is the largest segment, with a share about 70%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Ask for more details or sample of this report at: https://www.themarketreports.com/report/ask-your-query/1395968
The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479